Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

-Interim results of largest real-world study of TRIKAFTA® showed sustained improvement in lung function, reduction in pulmonary exacerbations frequency and lower rates of lung transplant and... | June 9, 2023

Related Keywords

France ,Paris ,France General ,Austria ,Cambridge ,Cambridgeshire ,United Kingdom ,Australia ,Germany ,Boston ,Massachusetts ,United States ,Vienna ,Wien ,London ,City Of ,German ,America ,Isabelle Fajac ,European Cystic Fibrosis Society ,Cystic Fibrosis Foundation Patient Registry ,Companies To Work ,Instagram ,Exchange Commission ,Twitter ,Facebook ,Linkedin ,Vertex Pharmaceuticals Incorporated Nasdaq ,European Union ,Youtube ,Vertex Pharmaceuticals Incorporated ,European Cystic Fibrosis Conference ,Late Breaking Science ,Professor Isabelle Fajac ,Cochin Hospital ,Assistance Publique H ,Paris Cit ,About Cystic ,Innovation District ,North America ,Top Employers ,Private Securities Litigation Reform Act ,Cystic Fibrosis ,While Vertex ,Vertex Pharmaceuticals Incorporated Stock Exchange ,News ,Information ,Press Release ,Results ,F ,Largest ,Study ,Howed ,Sustained ,Improvement ,N ,Young ,Reduction ,Pulmonary ,Exacerbations ,Frequency ,End ,Tower ,Rates ,Ransplant Vrtx Us92532f1003 ,